WallStSmart

Quest Diagnostics Incorporated (DGX)vsThermo Fisher Scientific Inc (TMO)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 300% more annual revenue ($47.35B vs $11.84B). TMO leads profitability with a 14.9% profit margin vs 9.5%. DGX appears more attractively valued with a PEG of 1.58. DGX earns a higher WallStSmart Score of 64/100 (C+).

DGX

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.37

TMO

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 6.5Value: 4.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DGXSignificantly Overvalued (-87.2%)

Margin of Safety

-87.2%

Fair Value

$111.82

Current Price

$250.81

$138.99 premium

UndervaluedFair: $111.82Overvalued

Intrinsic value data unavailable for TMO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DGX1 strengths · Avg: 8.0/10
EPS GrowthGrowth
28.7%8/10

Earnings expanding 28.7% YoY

TMO3 strengths · Avg: 8.7/10
Market CapQuality
$258.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
20.2%8/10

Strong operational efficiency at 20.2%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

DGX1 concerns · Avg: 4.0/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
2.034/10

Expensive relative to growth rate

P/E RatioValuation
36.8x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DGX

The strongest argument for DGX centers on EPS Growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : DGX

The primary concerns for DGX are PEG Ratio.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

TMO carries more volatility with a beta of 0.88 — expect wider price swings.

DGX is growing revenue faster at 10.0% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DGX scores higher overall (64/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quest Diagnostics Incorporated

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?